Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.64 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578998 | 0.84 | ERN1 (0.65) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL28225240 | 0.83 | MKNK1 (0.60) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL6040878 | 0.82 | ERN1 (0.56) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL6224414 | 0.82 | ALDH1A1 (0.58) | ERN1KDM4EALDH1A1TSHRTDP1 | |
| SCHEMBL4734973 | 0.81 | ERN1 (0.69) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL7677974 | 0.81 | ERN1 (0.69) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL6536258 | 0.81 | ERN1 (0.64) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL3933850 | 0.80 | ERN1 (0.56) | ERN1MKNK1MKNK2CYP19A1CYP11B1 | |
| SCHEMBL12766984 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL23326169 | 0.76 | MKNK1 (0.56) | ERN1MKNK1MKNK2CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| CN-1596240-A | Chalcone derivatives and their use for the treatment of diseases | ATHEROGENICS INC (US) | 2005-03-16 | — | — | CN | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040181075-A1 | Process of making chalcone derivatives | GENERAL ELECTRIC COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056727-A2 | PROCESS OF MAKING CHALCONE DERIVATIVES | ATHEROGENICS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | ERN1 1752/4885MKNK1 2457/4885MKNK2 2146/4885 |
| US-20040181075-A1 | Process of making chalcone derivatives | CYP2B6, LSS, CYP2E1 | ERN1 2696/4885MKNK1 2555/4885MKNK2 1486/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ERN1 1076/4885MKNK1 2786/4885MKNK2 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.